Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease

BACKGROUND: Resistance to endocrine therapy remains a major clinical problem in the treatment of oestrogen-receptor positive (ER+) breast cancer. Studies show androgen-receptor (AR) remains present in 80–90% of metastatic breast cancers providing support for blockade of AR-signalling. However, clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Simigdala, Nikiana, Pancholi, Sunil, Ribas, Ricardo, Folkerd, Elizabeth, Liccardi, Gianmaria, Nikitorowicz-Buniak, Joanna, Johnston, Stephen R., Dowsett, Mitch, Martin, Lesley-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068155/
https://www.ncbi.nlm.nih.gov/pubmed/29991699
http://dx.doi.org/10.1038/s41416-018-0158-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068155/
https://www.ncbi.nlm.nih.gov/pubmed/29991699
http://dx.doi.org/10.1038/s41416-018-0158-y

Ejemplares similares